Neomorph Inc. has entered into a collaboration and licensing agreement with Novo Nordisk A/S to discover, develop and commercialize molecular glue degraders.
Transthera Sciences (Nanjing) Inc. has announced the initiation of IND-enabling studies for TT-02332, a potent, selective and highly CNS-penetrating NLRP3 inflammasome inhibitor.
Isomab Ltd has closed a £7.5 million (US$9.4 million) seed financing round. The company is developing isoform-specific disease-modifying antibody treatments for serious and life-threatening diseases with an initial focus on peripheral ischemia.
A team at the Institute of Cellular Biology and Pathology ‘Nicolae Simionescu’ of Romanian Academy aimed to assess the effects of targeted siRNA for AP-1 silencing on restoring structural...
Pulmonary arterial hypertension (PAH) is a severe condition characterized by vasoconstriction and remodeling of the small pulmonary arteries, driven by a complement-dependent activation of macrophages, for which an effective treatment is lacking. Chinese researchers have investigated the potential of a complement C3 inhibitor polypeptide, CP40-KK, as an approach for treating PAH. To do this, they used a model in which PAH was induced in rats by monocrotaline.
Nextgen Bioscience Co. Ltd. has divulged ectonucleotide pyrophosphatase/phosphodiesterase family member 2 (ENPP2; autotaxin) inhibitors reported to be useful for the treatment of cancer, fibrosis, cardiovascular, inflammatory, respiratory, metabolic, eye and renal disorders, among others.<
Researchers from Mercer University have presented a middle cerebral artery/ferric chloride (MCA/FeCl3) thromboembolic mouse model of COVID-19-induced stroke and cerebrovascular complications.
Researchers from Broad Institute Inc. and affiliated organizations have reported data from a study that highlighted a new variant-to-gene-to-program (V2G2P) approach designed to link variants from genome-wide association studies (GWAS) to genes and identify their convergence onto specific disease-associated transcriptional programs.
Windtree Therapeutics Inc. has renewed its partnership with Chang Gung University to further research on SERCA2a, an important target for the company’s cardiovascular portfolio.
Researchers at the Spanish National Center for Cardiovascular Research (CNIC) have identified a new target that may open new avenues into pulmonary hypertension (PH) treatment. Their findings were published in Science Advances on Jan. 19, 2024.
RSS
